ONB
IOVA icon

Old National Bancorp’s Iovance Biotherapeutics IOVA Stock Holding History

Old National Bancorp’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-29,972
Closed -$287K – 702
2022
Q3 		$287K Sell
29,972
-500
-2% -$5.77K 0.01% 542
2022
Q2 		$336K Buy
+30,472
New +$399K 0.01% 476

Other funds holding IOVA

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Old National Bancorp's IOVA Position: Q4 2022 in Review

Old National Bancorp sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 29,972 shares — an estimated $287K sold.

Old National Bancorp first reported a position in IOVA in Q2 2022 and held it in 2 quarters. The position peaked at $336K in Q2 2022. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

  • Old National Bancorp reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Old National Bancorp sold 29,972 Iovance Biotherapeutics shares in Q4 2022, an estimated $287K.
  • Old National Bancorp first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 2 quarters.
  • Old National Bancorp's Iovance Biotherapeutics position peaked at $336K in Q2 2022.
  • 218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on Old National Bancorp's 13F filing for Q4 2022, filed 3 Feb 2023.